Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma
Open Access
- 1 April 2006
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 154 (4) , 525-531
Abstract
Objective: Treatment options for metastases of differentiated thyroid carcinoma (DTC) are limited due to decreased uptake of radioiodide (I-131). Therefore, strategies to improve I-131 uptake are mandatory. It has been suggested that retinoids have beneficial effects on iodide uptake in vitro and in humans. However, to date, only studies with 13-cis-retinoic acid have been performed in humans. We therefore decided to study the effects of 6 weeks of treatment with the retinoid X receptor activator bexarotene on I-131 uptake in patients with metastatic DTC. Design: Open prospective intervention study. Methods: Twelve patients with metastases of DTC, with insufficient uptake of I-131, received 6 weeks of treatment with 300 mg bexarotene/day. Prior to, and after this intervention, I-131 uptake was measured by whole-body scintigraphy and single photon emission tomography (SPECT) 3 days after 185 MBq I-131. Diagnostic imaging was preceded by two consecutive injections of recombinant human TSH. Results: Bexarotene treatment induced I-131 uptake in metastases of 8 out of 11 patients (one patient died for reasons not related to the study). However, uptake was only discernable at SPECT and had incomplete matching with metastases as visualized by CT scanning. Conclusions: Bexarotene partially restores I-131 uptake in metastases of DTC. The clinical relevance of this observation may be limited due to the differential responses of the different metastases within each patient and the low intensity of I-131 uptake.Keywords
This publication has 23 references indexed in Scilit:
- A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancerClinical Oncology, 2004
- Retinoic acid in patients with radioiodine non-responsive thyroid carcinomaJournal of Endocrinological Investigation, 2004
- Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- The promoter of the human sodium/iodide-symporter gene responds to retinoic acidMolecular and Cellular Endocrinology, 2001
- Retinoic Acid Redifferentiation Therapy for Thyroid CancerThyroid®, 2000
- Central Hypothyroidism Associated with Retinoid X Receptor–Selective LigandsNew England Journal of Medicine, 1999
- A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995Cancer, 1998
- Redifferentiation Therapy with Retinoids: Therapeutic Option for Advanced Follicular and Papillary Thyroid CarcinomaWorld Journal of Surgery, 1998
- Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical resultsExperimental and Clinical Endocrinology & Diabetes, 1996
- Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodineWorld Journal of Surgery, 1994